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Abstract
Background: The role of high dose therapy (HDT) with autologous stem cell transplantation
(AuSCT) for the treatment of bone and soft tissue sarcomas remains investigational. There are few
reports examining this strategy focusing on the adult population.
Methods: We retrospectively reviewed our experience of adult patients undergoing HDT and
AuSCT for 'paediatric' sarcomas.
Results: A total of 17 patients (14 male, 3 female) with median age at transplant of 24 years (range
20 – 41) were identified. The diagnosis was Ewings sarcoma/PNET (10), osteosarcoma (5) and
r h a b d o m y o s a r c o m a  ( 2 ) .  S t a t u s  p r i o r  t o  H D T ,  following conventional-dose chemotherapy +/-
surgery +/- radiotherapy, was complete remission (CR) (6), partial remission (PR) (6), stable
disease (1) and progressive disease (4). There was no transplant-related mortality. Two patients
remain disease free beyond four years and both received HDT as part of their primary therapy
(CR1 and PR1) however, the median progression free survival and overall survival following AuSCT
for the entire cohort was only 7 months (range: 2–92 months) and 13 months (range: 2 – 92
months), respectively.
Conclusion: HDT and AuSCT infrequently achieves prolonged remissions in adult patients and
should only be considered in patients who are in a PR or CR following conventional-dose therapy.
Further studies are required to define the role of HDT with AuSCT for adult patients with
sarcoma.
Introduction
The role of high dose chemotherapy (HDT) and autolo-
gous stem cell transplantation (AuSCT) for the treatment
of patients with sarcoma remains controversial. [1-3]
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The most common sarcoma for which HDT and AuSCT
has been investigated is the Primitive Neuroectodermal
Ectodermal Tumor (PNET) family of tumours which
includes Ewing's sarcoma (ES). Indeed, the median age at
diagnosis of PNET is14 years with 90% of patients being
under the age of 20 years.[4] In adults with PNET, the 5-
year overall survival (OS) following conventional-dose
therapy is between 38–60% while the progression-free
survival (PFS) is 27–59%. [5-7] Conversely, adult and
paediatric patients who fail to achieve a complete
response following surgery and conventional-dose chem-
otherapy are considered incurable and those with distant
metastases have only 9% – 33% long term survival.[8]
With respect to the role of HDT with AuSCT, no rand-
omized studies have been performed and most published
studies have included predominantly paediatric patients.
[9-16]
Similarly, there is limited data on the role of HDT and
AuSCT for osteosarcoma.[17] Again, studies to date have
predominantly involved paediatric patients.[1,18,19]
The most common soft tissue sarcoma (STS) in children is
rhabdomyosarcoma (RMS). Rare in adults, the disease
free survival at 5 years of adult STS (different histologies)
is approximately 10%. [20-25] In general, aggressive local
therapy consisting of maximum tumor bulk reduction
with surgery, with or without radiotherapy, is the corner-
stone of initial management and patients with STS who
are rendered disease free after surgery have a superior DFS
than those who are inoperable.[26] However, many
patients with STS are diagnosed with advanced-stage of
the disease and/or complete surgical resection of the
tumor is not feasible. Moreover, 40 to 60% of patients,
even after a primarily curative local therapy, will develop
metastases most frequently occurring within 2 to 3 years,
and they will ultimately die of the disease.[27] Adult
patients with RMS treated with conventional-dose therapy
have an even worse prognosis than children.[28] The role
of HDT and AuSCT for RMS remains unclear.[11,29]
Given the results with conventional-dose therapy, the role
of HDT with AuSCT for sarcomas has largely been
explored for patients with relapsed disease or those at
high-risk of relapse. Patients with adult STS generally are
poorly responsive to conventional-dose chemotherapy,
with doxorubicin and ifosfamide being the only available
agents showing response rates of greater than 20%. Com-
bination regimens generally do not add efficacy, but do
add toxicity.[21,24,27] For both agents, a dose-response
relationship has been shown. Despite this theoretical
rationale, the benefit of HDT is far from established in
paediatric population, let alone for adult patients with
sarcomas, with only a few studies reported and with small
patient numbers.[9-11,17,18,27,30]
Of the studies reported to date, improved survival rates
appear to be achieved for patients who achieve a complete
remission (CR) prior to HDT or for those where total
resection of tumor is feasible either before or after HDT.
[10-12,26,30] Conversely, HDT with AuSCT appears not
to improve outcome for PNET patients with metastatic
disease at presentation.[13-16,31] Here we report our
experience in treating adult patients with PNET, osteosar-
coma and RMS.
Materials and methods
A retrospective review of adult patients who underwent
HDT with AuSCT for sarcoma since 1992 at our institute
was performed. Toxicity was assessed according to the
World Health Organisation scale. Survival curves were
generated according to the Kaplan-Meier method with OS
and PFS calculated from the date of first stem cell
infusion.
Results
A total of 17 patients underwent HDT and AuSCT and
their characteristics are presented in Table 1 and included
ES (9), PNET (1), osteosarcoma (5) and RMS (2). There
were 14 males and 3 females with the median age at time
of AuSCT of 24 years (range 20–41 years). HDT was
administered as part of initial treatment (8), of which
only one was in CR, five in PR, one with progressive dis-
ease (ProD) and one with stable disease (SD); in first
relapse (7), of which four were in CR, one in PR and two
with ProD; fourth relapse (1) who was in CR. Disease sta-
tus immediately prior to HDT (following conventional-
dose chemotherapy and/or surgery and/or radiotherapy)
was CR (6), partial remission (PR) (6), stable disease (SD)
(1) and ProD (4). The source of autologous stem cells was
peripheral blood for 15 patients and bone marrow for two
patients. Eleven patients underwent a planned tandem
transplant.
HDT regimens were selected depending on prior therapy
or involvement in specific clinical trials. Patients with
osteosarcoma received carboplatin (700 mg/m2) and
etoposide (750 mg/m2)a. Four patients subsequently
received a second HDT and AuSCT with the same regimen
(2) or melphalan (180 mg/m2) and etoposide (60 mg/
kg)b (2). Patients with PNET/ES received a single course of
melphalan (180 mg/m2)c(2) or radionuclide
Samarium153  EDTMPd(1) or carboplatin (700 mg/m2)
and etoposide (750 mg/m2)e(1) or carboplatin (AUC =
21), thiotepa (900 mg/m2) and etoposide (750 mg/m2)f
(1) or tandem cycles with ifosfamide (12 g/m2), carbopl-
atin (AUC = 20) and etoposide (60 mg/kg)g followed by
and melphalan (180 mg/m2) and etoposide (60 mg/kg)b
(3);or tandem cycles with two cycles of carboplatin (700
mg/m2) and etoposide (750 mg/m2)a (1); or tandem
cycles with carboplatin (AUC = 21), thiotepa (900 mg/International Seminars in Surgical Oncology 2005, 2:12 http://www.issoonline.com/content/2/1/12
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m2) and etoposide (750 mg/m2)f followed by melphalan
(180 mg/m2) and etoposide (60 mg/kg)b (1). The two
patients with RMS were treated with tandem cycles of
HDT with AuSCT consisting of ifosfamide (12 g/m2), car-
boplatin (AUC = 20) and etoposide (60 mg/kg)g followed
by mitoxantrone (48 mg/m2), carboplatin (AUC = 20)
and etoposide (60 mg/kg)h (1) or ifosfamide (12 g/m2),
carboplatin (AUC = 16) mitoxantrone (64 mg/m2)i (1).
(Superscripted letters- indicating conditioning regimens
used in Table 1)
All patients experienced WHO grade 4 leukopenia, neu-
tropenia and thrombocytopenia after the HDT. The other
WHO grade 3–4 toxicities were mucositis (3), pulmonary
haemorrhage (1), ileitis (2) and haemorrhagic cystitis (1).
There were no transplant-related deaths.
Median follow up for all surviving patients was 12
months. Of patients in CR at the time of HDT (6), none
progressed during HDT and three of these patients have
subsequently relapsed and died with a median PFS of nine
months (range: 3–57 months). In patients entering HDT
in PR (6), two achieved CR after AuSCT – one (pt 17) sub-
sequently died of bilateral frontal haemorrhage at 7
months (not disease related), two achieved further reduc-
tion in tumour without achieving CR, one had SD and
one had ProD. All of the patients who had either ProD (4)
or SD (1) at the time of HDT subsequently progressed and
died.
Of the eight patients who were in CR following HDT,
three relapsed and died, four remain alive and disease free
(3 – 92 months). Two patients remain disease free beyond
four years (Pt 1 and Pt 16) and both received HDT as part
of their primary therapy (CR1 and PR1) however, the
median PFS and OS following AuSCT for the entire cohort
was only 7 months (range: 2–92 months) and 13 months
(range: 2 – 92 months), respectively. (Figures 1 &2).
Discussion
Given the relative chemotherapy-sensitivity of paediatric
sarcomas and the poor prognosis with conventional-dose
therapy for high-risk or relapsed disease, HDT with AuSCT
has been investigated. Due to the rarity of these tumours,
most studies have been retrospective, relatively small and
have examined heterogeneous patient populations. Thus,
despite some promising results demonstrating longer
than expected survival, the benefits of this strategy
remains uncertain.[27]
There is currently little data on the role of HDT for "pae-
diatric" sarcomas in the adult sarcoma population. Our
results in this group are disappointing. The median OS for
the entire population was only thirteen months (range: 2–
92 months) with a median PFS of seven months (range:
2–92 months) with only two patients remaining disease
free beyond four years. Meyer et al. demonstrated that
consolidation with high dose chemo-radiotherapy fol-
lowed by stem cell support failed to improve the
Table 1: Summary of Patient Characteristics and Outcome
No age at 
AuSCT
gender diagnosis surgery 
pre 
AuSCT
disease site at 
HDT
status at 
AuSCT
time 
between 
diagnosis 
and AuSCT 
(months)
Regimen* status 
post 
AuSCT
surgery 
post 
AuSCT
TTP 
(months)
status time to last 
follow up/
death 
(months)
1 39 M ES Y Rib CR1 11 e CR1 N NA A 57
2 20 F ES Y Lung CR2 38 c CR2 N 9 D 13
32 4 F E S Y B r a i n C R 2 3 7 f C R 2 N N A A 3
4 32 M ES N Pelvis PR1 4 g, b PR1 N 32 D 64
5 20 M ES N Scapula Clavicle PR1 6 g, b PR1 N 4 D 5
6 24 M PNET Y Brain PR2 52 f, b SD2 N NA A 4
7 41 M ES Y Tibia PR1 8 a, a PROG1 N 3 D 4
8 24 M ES N Lung Bones ProD2 40 c PR2 Y 5** D 5
9 27 M ES N Spine ProD1 7 d PROG1 N 5 D 2
10 26 M ES Y Spine SD1 23 g, b SD1 N 5 D 6
11 25 M OS Y Lung CR2 17 a, a CR2 N 7 D 15
12 21 M OS Y Lung CR4 84 a, b CR4 N NA A 12
13 24 M OS Y Node, Rib, Scapula CR2 24 a, a CR2 N 6 D 25
14 22 M OS Y Lung ProD2 34 a PR2 N 3 D 5
15 28 M OS Y Lung ProD3 32 a, b PR3 N 10 D 13
16 21 M RMS Y bladder PR1 13 g, h CR1 N NA A 92
17 34 F RMS Y face PR1 5 g, i CR1 N NA D 7
AuSCT = autologous stem cells transplant, TTP = time to progression,*See text for details of conditioning regimen, ES = Ewing's Sarcoma, PNET = 
Peripheral Neuroectodermal Tumor, OS = osteosarcoma, RMS = rhabdomyosarcoma, CR = Complete Remission, PR = Partial Remission, ProD = 
Progressive disease, SD = stable disease, NA = Not Applicable, A = alive, D = dead, **Travelled back to his native country and died (cause unknown 
but assumed to be disease-related).International Seminars in Surgical Oncology 2005, 2:12 http://www.issoonline.com/content/2/1/12
Page 4 of 7
(page number not for citation purposes)
probability of EFS in a cohort of patients with newly diag-
nosed metastatic Ewings Sarcoma.[16]
With respect to osteosarcoma, we utilized a tandem trans-
plant approach similar to that of the Italian sarcoma
group (two courses of high dose carboplatin and etopo-
side) and they have recently demonstrated in 32 patients,
with a median age of 15 years, a transplant-related mortal-
ity of 3.1% and a progression rate of 84% with a three-year
OS and DFS of 20% and 12%, respectively.[24]
Comparative results of other published trials in STS, most
of which include a paediatric population are presented in
Table 2. Of note, Blay et al. reported an eight percent five
year survival in adult patients with metastatic or locally
advanced irresectable STS [12] and Bokenmeyer et al[32]
reported results similar to ours in a cohort of 18 adult
patients with STS.
The European Organization for Research and Treatment
of Cancer demonstrated that predictors for improved sur-
vival for STS and bone sarcomas following HDT were per-
formance status, female gender, grade I tumors and the
achievement of a CR after first line treatment.[33] In our
study there was no clear predictors of durable remissions;
three of the six patients who underwent HDT in CR
relapsed, with a median PFS of nine months. (Range 3–57
months). Similarly, four of the eight who were in CR fol-
lowing HDT relapsed and died. It is of interest that one
patient remains disease free at 12 months undergoing
HDT and AuSCT in fourth CR.
Conclusion
Our results demonstrate that HDT and AuSCT infre-
quently achieves prolonged remissions in adult patients
and only prospective studies will definitely determine the
place of HDT in this group. Our data support that
Kaplan-Meier Curve of Progression free Survival for the entire cohort Figure 1
Kaplan-Meier Curve of Progression free Survival for the entire cohort.International Seminars in Surgical Oncology 2005, 2:12 http://www.issoonline.com/content/2/1/12
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contention that HDT should only be considered in
patients who are in a PR or CR following conventional-
dose therapy.
Abbreviations
AuSCT Autologous stem cell transplantation
CR Complete remission
ES Ewing's sarcoma
HDT High dose therapy
Kaplan-Meier Curve of Progression free Survival for the entire cohort Figure 2
Kaplan-Meier Curve of Progression free Survival for the entire cohort.
Table 2: Summary of High Dose Chemotherapy Studies in Soft Tissue Sarcomas
Author Number of Pts Median Age (Range) R.F.S (months) O.S. (months)
Kasper 29 27 30.6 (13–59) 12 16.5
Blay 12 30 34 (17–57) 7 19
Samuel 34 23 not stated - 5.1
Dumontet35 22 16 (3–45) 15 19
Bokemeyer32 18 45 (25–37) 8 13
Kang36 24 24 (11–53) 6 10
Schlemmer37 55 not stated - 23International Seminars in Surgical Oncology 2005, 2:12 http://www.issoonline.com/content/2/1/12
Page 6 of 7
(page number not for citation purposes)
OS Overall survival
PR Partial remission
PNET Primitive Neuroectodermal Ectodermal Tumor
PFS Progression free survival
ProD Progressive Disease
RMS Rhabdomyosarcoma
STS Soft tissue sarcoma
SD Stable disease
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